anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a drug capable of improving resistance and a preparation method thereof. The resistance refers to the situation that each system of a human body cooperates with each other and acts in close coordination under the control of a central nervous system so as to guarantee normal operation of vital movement. An immune system is capable of defending intrusion by external pathogenic organisms, thereby preventing a variety of diseases caused by intrusion of external pathogenic organisms. The defense capability of the human body is resistance. The drug is prepared from Chinese magnoliavine fruit, ginseng, Poria cocos, black sesame, American ginseng, glossy privet fruit, polyporus, Radix Codonopsis, tortoiseshell, pseudostellaria root, oriental waterplantain rhizome, turtle shell, Radix Astragali, yerbadetajo herb, lotus seed, bighead atractylodes rhizome, mulberry, Chinese yam, Flos Farfarae, wolfberry, hyacinth bean, lily, arborvitae seed, licorice root, polygonatum rhizome, jujube, sword bean, Polyghace seche, cerealose, dendrobium, tangerine pericarp, honey, Radix Asparagi, pilose antler, tuber of dwarf lilyturf and deerhorn glue. The above-mentioned bulk drugs are combined together and exert synergistic effect, so the drug is capable of effectively treating cold.
A single group rolling prospective cohort study with a target of 15 participants will evaluate the initial design prototype using the an existing adaptive rower design. Participants will have one visit to the University of South Carolina Rehabilitation lab. Participants will receive an orientation to the rowing machine and available handle, grip and trunk support options. Training will be provided in proper rowing technique and use of the rate of perceived exertion scale. Participants will be fitted with a heart rate monitoring device and resting heart rate established. Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity. Participants heart rate will be monitored and recorded throughout the testing period, with rate of perceived exertion at start, midpoint and end of steady state period, and at start, at each interval, and at end in interval period.
Dysgenetic polycystic disease, also known just as polycystic disease, is a very rare developmental abnormality affecting the salivary gland duct system. This entity has been reported in only 21 patients previously, although a careful review suggests only 16 patients have histological evidence of the disease. In previously reported cases, this lesion most commonly presents as either an incidental finding or as a swelling affecting the parotid glands bilaterally, or rarely the submandibular glands bilaterally. This case report details the first time dysgenetic polycystic disease is found affecting the minor salivary glands of the tongue in a 55-year-old male. Histochemical and immunohistochemical stains are presented and include positivity for AE1/AE3 and p63, and negativity for progesterone receptor, androgen receptor, mammaglobin, S100 and BRAF V600E. PAS-D and Congo Red highlight special microamyloid spheroliths structures intraluminally.
At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery. They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
PURPOSE: The aim of this study was to explore the association of cardiac CT-based left atrium (LA) structural and functional parameters and left atrial epicardial adipose tissue (LA-EAT) parameters with postablation atrial fibrillation (AF) recurrence within 2 years.
MATERIALS AND METHODS: Contrast-enhanced cardiac CT images of 286 consecutive AF patients (median age: 65 y; 97 females) who underwent initial ablation between June 2018 and June 2020 were retrospectively analyzed. Structural and functional parameters of LA, including maximum and minimum volume and ejection fraction of LA and left atrial appendage (LAA), and LA-EAT volume, were measured. The body surface area indexed maximum and minimum volume of LA (LAVI max , LAVI min ) and LAA (LAAVI max , LAAVI min ), and LA-EAT volume index (LA-EATVI) were calculated. Independent predictors of AF recurrence were determined using Cox regression analysis. The clinical predictors were added to the imaging predictors to build a combined model (clinical+imaging). The predictive performance of the clinical, imaging, and combined models was assessed using the area under the receiver operating characteristics curve (AUC).
RESULTS: A total of 108 (37.8%) patients recurred AF within 2 years after ablation at a median follow-up of 24 months (IQR=11, 32). LA and LAA size and LA-EAT volume were significantly increased in patients with AF recurrence ( P <0.05). After the multivariable regression analysis, LA-EATVI, LAAVI max , female sex, AF duration, and stroke history were independent predictors for AF recurrence. The combined model exhibited superior predictive performance compare to the clinical model (AUC=0.712 vs. 0.641, P =0.023) and the imaging model (AUC=0.712 vs. 0.663, P =0.018).
CONCLUSION: Cardiac CT-based LA-EATVI and LAAVI max are independent predictors for postablation AF recurrence within 2 years and may provide a complementary value for AF recurrence risk assessment.
Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.
Overdosage with pseudoephedrine may manifest itself as excessive CNS stimulation resulting in excitement, tremor, restlessness and insomnia. Other effects may include tachycardia, hypertension, pallor, mydriasis, hyperglycemia and urinary retention. Severe overdosage may cause tachypnea or hyperpnea, hallucinations, convulsions or delirium, but in some individuals there may be CNS depression with somnolence, stupor or respiratory depression. Arrhythmias (including ventricular fibrillation) may lead to hypotension and circulatory collapse. Severe hypokalemia can occur, probably due to a compartmental shift rather than a depletion of potassium. No organ damage or significant metabolic derangement is associated with pseudoephedrine overdosage. Overdose with dextromethorphan include CNS effects as most prevalent, such as psychosis, hallucinations, mania, seizures, ataxia, dizziness, and psychological dependence. Urinary retention and tachycardia have also been reported. Very high doses may lead to respiratory depression coma/unconsciousness, and cyanosis.Manifestations of antihistamine overdosage may vary from CNS depression (sedation, apnea, cardiovascular collapse) to stimulation (insomnia, hallucinations, tremors or convulsions). Other signs and symptoms may be dizziness, tinnitus, ataxia, blurred vision, and hypotension. Stimulation is particularly likely in children, as are atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing; hyperthermia and gastrointestinal symptoms).
Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
Obesity has emerged as an important global health challenge, significantly influencing the incidence and progression of various cancers. This comprehensive review elucidates the complex relationship between obesity and oncogenesis, focusing particularly on the role of dysregulated signaling pathways as central mediators of this association. We delve into the contributions of obesity-induced alterations in key signaling cascades, including PI3K/AKT/mTOR, JAK/STAT, NF-κB, and Wnt/β-catenin to carcinogenesis. These alterations facilitate unchecked cellular proliferation, chronic inflammation and apoptosis resistance. Epidemiological evidence links obesity with increased cancer susceptibility and adverse prognostic outcomes, with pronounced risks for specific cancers such as breast, colorectal, endometrial and hepatic malignancies. This review synthesizes data from both animal and clinical studies to underscore the pivotal role of disrupted signaling pathways in shaping innovative therapeutic strategies. We highlight the critical importance of lifestyle modifications in obesity management and cancer risk mitigation, stressing the benefits of dietary changes, physical activity, and behavioral interventions. Moreover, we examine targeted pharmacological strategies addressing aberrant pathways in obesity-related tumors and discuss the integration of cutting-edge treatments, including immunotherapy and precision medicine, into clinical practice.
FIELD: chemistry. ^ SUBSTANCE: disclosed is a method of treating or preventing malignant tumours whose cells express EphA4. The method involves administration of the anti-EphA4 antibody, where the antibody has human IgG1, has VH and VL regions, each containing three corresponding CDR. Described is a pharmaceutical composition based on the antibody for use in the said method. ^ EFFECT: invention can be used in pancreatic cancer therapy. ^ 11 cl, 2 dwg, 1 tbl, 1 ex
Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
ETHNOPHARMACOLOGICAL RELEVANCE: Panax ginseng (P. ginseng) C. A. Meyer. has been used extensively globally as a medicine. It has a therapeutic effect on sleep and is an attractive alternative for patients with insomnia. The United States Patent of Invention has approved the use of P. ginseng alcohol extract (GAE) in nutraceuticals or food to improve sleep. It has shown promise as an effective therapeutic agent for improving sleep and cognition. However, its mechanism of action is not yet fully understood.
AIM OF THE STUDY: To investigate the therapeutic benefits of GAE on sleep and cognition and its underlying mechanism in aged sleep-deprived rats, with a focus on orexin-mediated autophagy function.
MATERIALS AND METHODS: We conducted in vivo tests in an aged sleep-deprivation rat model produced using p-chlorophenylalanine (PCPA) coupled with modified multi-platform method to examine the therapeutic effects and mechanisms of GAE. A pentobarbital sodium-induced sleep test and water maze were used to assess sleep and cognitive performance, respectively. An enzyme-linked immunosorbent assay was used to determine orexin levels and aging and sleep markers in serum and hypothalamic tissues. Hematoxylin-eosin staining and Nissl staining were used to assess histopathological changes, and autophagy levels were assessed using transmission electron microscopy, immunofluorescence. Western blot and immunohistochemical staining were performed to detect the levels of orexin, orexin-receptor proteins, and autophagy-associated proteins to study the effects of GAE on hippocampal neurons, and the underlying mechanisms.
RESULTS: In aged sleep-deprived rats, GAE treatment prolonged sleep duration, improved cognitive function, prevented hippocampal neuronal damage, increased the number of Nissl bodies, improved aging and sleep markers, and enhanced the LC3A/B expression in autophagosomes and neurons. The amount of orexin in serum and hypothalamic tissue and OX1R, OX2R, and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) proteins also reduced, which resulted in the inhibition of the PI3K/Akt/mTOR pathway and activation of the autophagy process.
CONCLUSIONS: GAE may reduce hypothalamic orexin secretion and interact with orexin receptors to inhibit the PI3K/Akt/mTOR signalling network and activate autophagy. This may be a potential mechanism of action of GAE in regulating sleep-related cognitive function.
All research activites are on hold due to COVID-19. We updated enrollment start date and we will update primary completion date and study completion date later.

This project is focused on identifying mechanistic pathways to guide future therapeutic interventions for central sleep apnea (CSA) based on the strong premise that multi-modality therapy - aiming to normalize respiration- is the requisite path to mitigating the long-term adverse consequences of CSA. The central hypothesis is that CSA reflects a combination of physiologic perturbations and may require combined modality therapy targeting different parts of the ventilatory feedback loop. The proposed studies will test combination therapies, including PAP plus a pharmacological agent. This will also increase the clinical relevance of the proposed studies since PAP therapy is typically prescribed as the initial treatment of CSA. To achieve the objectives of this proposal, the investigators will test the following three specific aims. Specific Aim (1) is to determine the effect of combination therapy aiming to dampen chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to each intervention alone in reducing central apnea-hypopnea index (CAHI) and the CO2 reserve during sleep in patients with central sleep apnea. Specific Aim (2) is to determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in patients with CSA compared to placebo. Specific Aim (3) is to determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with central sleep apnea. This Novel project seeks to identify physiologic pathways that can, in combination with PAP therapy, improve the effectiveness of treatment for patients with CSA. The proposed studies are innovative, feasible and will provide a much-needed roadmap for future clinical trials that are likely to transform the care of central apnea in Veterans.
<P>PROBLEM TO BE SOLVED: To provide an implantable medical device releasing a bioactive substance via a porous layer at a controlled speed.  <P>SOLUTION: This coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system; a coating layer 16 posited on one surface of the structure; and a layer of a bioactive material posited on at least a portion of the coating layer, wherein the coating layer 16 provides for the controlled release of the bioactive material from the coating layer. In addition, a porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer includes a polymer and provides the controlled release of the bioactive material therethrough. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides the controlled release of the bioactive material. The polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, and merely by condensation of a monomer vapor.  <P>COPYRIGHT: (C)2010,JPO&INPIT
This article aims to summarize the current knowledge on the evaluation and follow-up of urethral stricture (US) treatments through a comprehensive literature review and to propose a detailed follow-up protocol post-treatment. There is no consensus on how to assess US treatments. It must address both anatomical factors (evaluated by the urologist) and functional factors (evaluated by the patient). Anatomical assessment is guided by uroflowmetry, combined with a questionnaire validated in French, the IPSS or the USP, pending validation of a dedicated tool. If the IPSS is used, continence must also be assessed. Suspicion of recurrence on these criteria should lead to reassessment of urethral caliber (endoscopy and/or urethrography). The evaluation of areas other than miction (sexuality, pain, morbidity in the event of buccal harvesting) should not be neglected, particularly after urethroplasty. A follow-up protocol is proposed based on this literature review.
The invention relates to the technical field of wine brewing and particularly relates to a preparation method of a maize nourishing wine. The maize nourishing wine is brewed by taking a maize wine as a base wine and taking angelica sinensis, ginseng, wolfberry and red dates as auxiliary materials. In the brewing process, the maize nourishing wine is strictly sealed in an underground natural cave for several years according to a traditional brewing method, and the wine is natural amber, mellow and sweet in taste as well as strong, pure and aromatic in flavor. When a woman is in the puerperal period, fresh eggs and the maize nourishing wine are boiled to be drunk, so that nutrients can be rapidly supplemented for lying-in women, a parent body can be regulated to promote breast milk secretion, a health milk source can be rapidly provided for infants, and thus the maize nourishing wine is a necessary health wine for breast feeding. Meanwhile, the maize nourishing wine can also help women restore the physique and keep youth forever while restoring vigor of the lying-in women. If being drunk for a long term, the maize nourishing wine has the effects of enriching yin and nourishing the kidneys, tonifying the spleens and warming the liver, promoting the secretion of saliva or body fluid and moistening the stomach, smoothing the intestine and relieving constipation, activating muscles and strengthening the body, preventing decay and beautifying the face, promoting blood circulation to restore menstrual flow and the like. The prepared wine product has extremely good features so as to be very good in market prospect.
The present invention relates to Chinese medicinal food for hair improvement, which prevents the premature growth of gray hair, promotes hair growth, and can prevent hair loss, and which prevents various side effects and enhances health by using only natural Chinese medicinal ingredients. The Chinese medicinal food for hair improvement is manufactured by mixing Eclipta prostrata L., Rehmanniae Radix Preparata, Pleuropterus multiflorus TURCZ., Mori Fructus, the flesh of walnut, the leaf of Perilla frutescens var. japonica, a green tea leaf, Houttuynia cordata Thunb., a young mulberry leaf and Acyranthes bidentata Blume. The Eclipta prostrata L. is washed, is dried, is soaked in rice wine, and is used after a three-time repetitive steaming and drying process. The Rehmanniae Radix Preparata is used after a nine-time repetitive steaming and drying process of Rehmanniae Radix Recens soaked in glutinous rice wine. The Mori Fructus is put into a container provided with a cover on the upper part, is turned in a state that the cover is partially opened, is put into soybean paste, and is aged for three months, followed by being used. The kernel of walnut is wrapped in hemp cloth and is put into a pot in which water and rice are contained and boiled before the water is boiled, and the flesh of walnut is used after a nine-time repetitive boiling and drying process of the kernel of walnut. The leaf of Perilla frutescens var. japonica, the green tea leaf, and the Houttuynia cordata Thunb. are washed and dried to be used. The young mulberry leaf is soaked in glutinous rice wine and is used after one steaming and drying process. The Acyranthes bidentata Blume is soaked in rice wine and is used after a three-time repetitive steaming and drying process. The Pleuropterus multiflorus TURCZ. is used after one steaming and drying process using black bean and a nine-time repetitive steaming and drying process using white bean.
Patients receive nutrition counseling with a nutritionist over 60 minutes, receive FMD over 4 days for 3 cycles of immunotherapy and educational guidelines for day 5 to transition to a regular diet. Patients undergo blood sample collection throughout the study.
Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days plus a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
Antibodies to HtrA1 and methods of using such antibodies are described herein. The antibodies described herein are raised against HtrA1 and variants of HtrA1 as defined herein. The antibodies disclosed herein are useful in treating disease or injury of the eye. For example, in one embodiment, HtrA1 antibodies may be used to treat age-related macular degeneration (AMD) in both its wet and dry forms, diabetic retinopathy (DR), retinopathy of prematurity (ROP) or macular edema. In another embodiment, HtrA1 antibodies may be used to treat choroidal or retinal neovascularization associated with or resulting from disease or injury. In another embodiment, the methods of the present invention include use of HtrA1 antibodies to treat ischemia-induced retinal neovascularization resulting from vascular damage, occlusion or leak resulting from disease or injury. The methods described herein include administering a therapeutically-effective amount of one or more HtrA1 antibodies to a subject. Pharmaceutical compositions of antibodies to HtrA1 are also described herein.